Butterfly Network (BFLY) Q1 2023: Software and Services Revenue Jumps 45% as Monetization Strategy Shifts
Butterfly Network’s Q1 revealed a decisive pivot toward software-driven growth, highlighted by a 45% surge in software and services revenue and a rising gross margin mix. New CEO Joe DeVivo is actively reassessing the go-to-market and monetization approach, prioritizing AI-enabled applications and enterprise software to unlock higher-margin opportunities. Investors should watch for updated strategy and guidance next quarter as the company navigates channel disruption and commercial execution challenges.
Summary
- Software Monetization Accelerates: Butterfly’s shift to software-first is driving margin expansion and recurring revenue growth.
- Leadership Reset in Progress: New CEO is reevaluating strategy and commercial execution amid channel disruption.
- Outlook Hinges on Execution: Updated guidance and clearer strategic direction expected in Q2 as pipeline matures.
Business Overview
Butterfly Network develops and sells handheld, chip-based ultrasound devices and related software, aiming to democratize medical imaging by making it accessible and easy to use at the point of care. The business generates revenue through device sales, subscription-based software (including AI tools and enterprise solutions), and services across healthcare, education, and veterinary markets. Major segments include direct U.S. sales, international distribution, global health initiatives, and veterinary applications.
Performance Analysis
The quarter underscored a pivotal transition: While overall revenue remained flat, Butterfly’s software and services revenue jumped 45% year-over-year, now comprising 43% of total revenue—up from 28% a year ago. This shift reflects growing adoption of subscription offerings and enterprise software deployments, particularly in U.S. health systems and educational institutions.
Product revenue declined 20% due to lower hardware volume outside global health, but gross margin expanded to 59%, driven by a richer software mix and improved manufacturing efficiency. The company’s U.S. direct channel posted a 15% sales increase, offset by softness in e-commerce, international, and veterinary segments. Adjusted EBITDA loss narrowed substantially, aided by cost reductions and operating leverage from higher-margin software.
- Software Mix Drives Margin: Higher subscription and services mix, up 15 percentage points YoY, boosted profitability despite hardware declines.
- Direct Channel Outperforms: U.S. direct sales rose 15%, reflecting stronger enterprise traction and successful hospital-focused salesforce restructuring.
- Channel Disruption Weighs: Delayed onboarding of third-party distributors and international softness offset U.S. gains, highlighting execution risk.
Cash burn moderated with $198 million in cash and equivalents at quarter-end, providing runway as the company realigns its commercial and product strategy under new leadership.
Executive Commentary
"I view Butterfly as a technology-empowered software company. Our chip-based hardware provides us an accessible and growing user base that our software can be sold to, providing incremental software opportunities."
Joe DeVivo, Chairman and CEO
"Gross profit margin was 59% for the first quarter, which compares to 54% in Q1 2022. This increase was primarily due to a higher average selling price in addition to product mix reflecting a higher proportion of subscription revenues."
Heather Goetz, Executive Vice President and CFO
Strategic Positioning
1. Software-Centric Monetization
Butterfly is aggressively shifting its business model toward software and AI-enabled solutions, aiming to monetize its installed hardware base via new algorithm-driven applications and enterprise software. This approach targets higher gross margins and recurring revenue, positioning Butterfly closer to a SaaS (software-as-a-service) model within medtech.
2. Enterprise and Education Channel Expansion
Hospital systems and academic institutions are now core to Butterfly’s commercial strategy, with recent large-scale Blueprint deployments and partnerships. These relationships not only drive device adoption but also create sticky software revenue streams and act as reference accounts for broader market penetration.
3. AI and Data Platform Leverage
Butterfly’s proprietary ultrasound-on-chip hardware and cloud data repository are being harnessed to accelerate FDA-cleared AI tools (e.g., Beeline for pulmonary scans), with a roadmap to monetize these applications across the existing customer base. This positions Butterfly as both a hardware innovator and a data-driven platform company.
4. Channel and Go-To-Market Realignment
The company is restructuring its sales approach, focusing direct resources on high-value hospital accounts and relying more on distributors for broader reach. Execution gaps in onboarding distributors and international markets remain a risk, but the strategy aims to optimize cost-to-serve and accelerate scale.
5. Home and Adjacent Market Opportunity
Butterfly’s leadership sees significant untapped potential in home and alternative site care, leveraging its portable technology and AI tools to move beyond traditional hospital settings. Regulatory and commercial pathways are under review, with updates expected as the CEO refines the go-to-market approach.
Key Considerations
This quarter marks a strategic inflection point as Butterfly transitions from device-led to software-led growth, with implications for margin structure, customer relationship depth, and recurring revenue visibility.
Key Considerations:
- Software Upsell Potential: The company’s large installed base offers leverage for incremental software and AI module sales, supporting higher gross margin and customer stickiness.
- Execution on Channel Strategy: Timely onboarding of third-party distributors and international expansion are essential to offset U.S. direct channel concentration.
- AI Differentiation: FDA-cleared tools and a unique image database underpin Butterfly’s competitive moat, but speed to market and monetization are critical.
- Cash Runway and Efficiency: Strong cash position and lower burn rate provide flexibility, but further cost discipline and ROI-driven investment are required to reach breakeven.
Risks
Execution risk is elevated as Butterfly navigates leadership transition, channel disruption, and a complex shift toward software monetization. International and distributor channel softness, combined with slower-than-expected new partner onboarding, could weigh on near-term growth. Competitive pressures from established imaging incumbents and regulatory hurdles for home and AI applications remain material uncertainties. The pause in full-year guidance underscores the need for clear, credible strategy delivery in the coming quarters.
Forward Outlook
For Q2 2023, Butterfly guided to:
- Sequential revenue growth, but “flattish” versus Q2 2022
- EBITDA improvement from Q1 as cost reductions are fully realized
For full-year 2023, management did not reaffirm guidance, citing the need for a strategic review by the new CEO. Key factors highlighted include:
- Continued U.S. direct channel strength with major academic partnerships
- Distribution partners expected to gain traction, though at a slower pace
- Veterinary channel expansion muted; international and global health revenue expected to remain soft
Takeaways
Butterfly’s Q1 signals a business model pivot and operational reset, with software and AI monetization now the core growth engine. Execution on channel expansion and new product launches will determine whether this strategy translates to sustainable profitability and scale.
- Software-Driven Margin Expansion: The rising software mix is structurally improving gross margin and recurring revenue, but hardware softness and channel disruption offset gains.
- Leadership Realignment Underway: New CEO’s strategic review and commercial reset introduce near-term uncertainty but may unlock long-term value if execution improves.
- Pipeline and Guidance Watch: Investors should look for tangible progress on AI monetization, distributor ramp, and home/adjacent market entry in the second half of the year.
Conclusion
Butterfly Network’s Q1 shows the early results of a deliberate pivot toward software and AI-driven growth, with margin and recurring revenue benefits starting to materialize. The next phase depends on the new leadership’s ability to execute on commercial realignment and deliver on the promise of its robust innovation pipeline.
Industry Read-Through
Butterfly’s transition toward software-centric, AI-enabled medical devices reflects a broader medtech trend where recurring software revenue and data-driven applications are becoming key value drivers. Competitors focused solely on hardware risk margin compression, while those leveraging proprietary data and AI stand to capture premium economics. Hospital and education channel strategies are increasingly critical for device makers seeking scale and embeddedness. The shift toward home and alternative site care, if successful, could open new frontiers for point-of-care imaging and reshape care delivery models across the sector.